Search results

Alaska is the largest state by land area in the United States. It is also the most diverse in its climate and topography. This chapter will examine the geographic and operational features that make Alaska a unique environment for air cargo logistics. Some of these features sustain its competitive advantage in international air cargo activity. In particular, Ted Stevens Anchorage International Airport (ANC) is a major air cargo gateway for Asia trade with the contiguous United States. An overview of the airport's exclusive air cargo transfer operations will be discussed. Alaska is also one of the least populous states, with about half of the population living in and around the Anchorage area. Due to this, towns and villages ranging from the temperate Alaska Panhandle to well above the Arctic Circle remain dependent on commercial air cargo activity. The federal air cargo program known as Alaska Bypass will be examined as remaining both unique and necessary for the state's socio-economic development.

The purpose of the paper is to explore the degree to which the drug industry is changing from a product orientation to a more strategic category captain management (CCM) approach.

The paper is based on secondary research sources.

The paper shows that the drug industry is starting to move toward a more strategic approach to partner with downstream customers as opposed to a sales‐oriented approach.

The paper suggests that there is another fundamental way to compete for the drug industry, more as partners than just suppliers.

There are significant social implications. The drug industry has been battered for serious faults regarding regulatory issues. The industry has come under scrutiny for questionable marketing conduct. By providing more than just physical product and hard sell tactics, CCM can serve as an alternative model for the drug industry to compete.

The paper is unique in that timing is ripe for this kind of analysis. To the best of the author's knowledge, there is no research to date on the issue of substantial ways that the pharmaceutical industry can change its business model.